Semaglutide (Ozempic, Wegovy) Semaglutide is another GLP-1 agonist that has been in the news lately due to its reported efficacy as a weight loss agent
If validated in a clinical trial, the observed reduction in breast cancer risk associated with GLP-1 use would be somewhat less than, but broadly comparable to, that seen with established preventive interventions such as bariatric surgery and anti-estrogen therapies, she said
doi: 10.1111/dom.14358 Summary Keywords glucose homeostasis, insulin resistance, intestinal hormones, PYY, Y2 receptor Citation Liu C, Ren N, Zhang H and Ma J (2026) The role of PYY in improving insulin resistance
[DOI] [PMC free article] [PubMed] [Google Scholar] 222.Gouveia Z., Carlos A.R., Yuan X., Aires-da-Silva F., Stocker R., Maghzal G.J., Leal S.S., Gomes C.M., Todorovic S., Iranzo O., et al
[PubMed] [Google Scholar] 96
It is estimated that, globally, there are currently 122.8 million people 6599 years of age with diabetes, a figure that is expected to increase to 253.4 million in 2045 [1]
.png)
